PECAM1 and breast cancer: In the current study, a comparative assessment of CNS and endothelial lesions biomarkers (i.e., ICAM-1, PECAM-1, NSE, and anti-NR-2 antibodies), was performed in BC patients with post-treatment symptoms and in both with chronic ischemic brain disease with and without hemodynamic asymptomatic carotid stenosis.